Sobi signs $450M deal for rare disease drug emapalumab, boosting its inflammation, I/O pipeline

Swedish drugmaker Sobi has bought global rights to a late-stage rare disease drug from Novaimmune SA, building up its inflammation business and potentially lining up a good chunk of new revenue should the drug get approved.